You are here

Home » Content

SAPD HASTALARIND A TT VİRÜS (TTV) ENFEKSİYONU ve PREVELANSI

TT VIRUS (TTV) INFECTION AND PREVALENCE IN CAPD PATIENTS

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2001

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Transfusion Transmitted Virus (TTV) is a DNA virus and it was first isolated from a patient with post-transfusion hepatitis in 1997. Prevalence of TTV differs in different geographic areas. There are evidences that virus is transmitted through not only by parenteral way but also through other routes. However, potential pathophysiologic role of TTV in chronic liver diseases remains to be established. In this study, we investigated the prevalence of TTV in continuous ambulatory peritoneal dialysis (CAPD) patients and in healthy controls without history of blood transfusion. Sixty-three CAPD patients and fourty-three healthy controls were included into the study. TTV DNA was detected by semi-nested PCR method. TTV-DNA was detected in %o44.4 of CAPD patients and %30.2 of healthy controls (p>0.05). The prevalence of anti-HCVpositivity and HBsAg positivity was %17.4 and %3.1 in CAPD patients, respectively. History of blood transfusion was present in %30 of patients and prevalence of TTV was %36.8 and %34.1 in patients with and without history of blood transfusions, respectively (p>0.05). The prevalence of TTV was 45.4% among the and HCVpositive patients whereas it was 44.2% among the anti HCV negative patients (p>0.05). Serum ALT level was high in 3 patients and among these patients one was positive for anti-HCV, one was positive for TTV and one was negative for the three hepatitis viruses. . In conclusion, we demonstrated that TTV is not more prevalent in CAPD patients compared to healthy controls. We also could not demonstrate any relation between presence of TTV and blood transfusion, presence of other viruses and liver disease.
Bookmark/Search this post with
Abstract (Original Language): 
Transfusion transmitted virus" (TTV) adı da verilen virus ilk kez 1997 yılında post-transfüzyon hepatitli bir hastanın serumundan izole edilen yeni bir DNA virüsüdür. Sıklığı belirgin coğrafik farklılıklar gösteren bu virüsün parenteral geçişinin yanısıra diğer yollardan da bulaşabileceğine ilişkin bulgular vardır. Bu virüsün karaciğer hastalıklarındaki potansiyel rolü de henüz tam olarak belirlenmiş değildir. Bu çalışmada sürekli ayaktan periton diyalizi (SAPD) tedavisindeki hastalarda ve kan transfüzyon öyküsü olmayan sağlıklı kontrollerde TTVprevelansı ve SAPD hasta gurubunda bu virüsün karaciğer hastalığı ile ilişkisi araştırıldı. Çalışmaya, halen CAPD tedavisinde olan 63 hasta ile sağlıklı ve transfüzyon öyküsü olmayan 43 birey kontrol gurubu olarak alındı. TTV-DNA 'sı semi-nested PCR yöntemi ile tayin edildi. TTV-DNA pozitifliği hasta gurubunda %44.4 oranında, kontrol grubunda ise %30.2 oranında bulundu (p>0.05). Hasta gurubunda anti-HCV%17.4 ve HBsAg ise %3.1 oranında saptandı. Hastaların %30.2'sinde kan transfüzyonu öyküsü alındı ve bunların %36.8'inde TTV pozitif olmasına karşılık, kan transfüzyonu yapılmayan hastalarda ise TTV pozitifliği %34.1 oranında (p>0.05) tespit edildi. Anti-HCV pozitif bulunan 11 hastanın 5'inde (%45.4) TTV pozitif olmasına karşılık, anti-HCV negatif 52 hastanın 23 ünde (%44.2) TTV pozitif bulunmuştur. ALT yüksekliği izlenen üç hastanın birinde TTV pozitif, birinde anti-HCV pozitif, ve üçüncüsünde ise her üç hepatit virüsününde negatif olduğu gözlendi. Sonuç olarak, TT virüsünün SAPD hastalarında sağlıklı popülasyondan daha sık olarak görülmediği, diğer hepatit virüslerinin varlığı ile yada kan transfüzyonu veya karaciğer hasarı ile ilişkisinin olmadığı kanısına varılmıştır.
FULL TEXT (PDF): 
PDF icon pdf_tndt_334.pdf
  • 2
93-97
  • Turkish

REFERENCES

References: 

1. Nishizawa T, Okamoto H, Konishi K, et al. A novel DNA virüs (TTV) associated with elevated transaminase levels in posttransfusion hepatitis of unknown etiology. Biochem Biophys Res Commun 1997;241:92-7.
2. Okamoto H, Nishizawa T, Kato N, et al. Molecular cloning and characterization of a novel DNA virus (TTV) associated with posttransfusion hepatitis of unknown etiology. Hepatol Res 1998; 10: 1-16.
3. Tanaka H, Okamoto H, Luengrojanakul P, et al. Infection with an unenveloped DNA virus (TTV) associated with posttransfusion non-A to G hepatitis in hepatitis patients and healthy blood donors in Thailand. J of Med Virol 1998;56: 234-238.
4. Charlton M, Adjei P, Poterucha J et al. TT-virus infection in North American blood donors, patients with fulminant hepatic failure, and cryptogenic
cirrhosis. Hepatology 1998;28: 839-842.
5. Naoumov NV, Petrova EP, Thomas MG et al. Presence of a newly deseribed human DNA virus in patients with
liver disease. Lancet 1998;352: 195-197.
6. Gimenez-Barcons M, Forns X, Ampurdanes S, et al. Infection with a novel human DNA virus (TTV) has no pathogenic significance in patients with liver diseases. J of Hepatology 1999;30: 1028-1034.
7. Ikeda H, Takasu M, Inoue K, et al. Infection with an unenveloped DNA virus (TTV) in patients with acute or chronic liver disease or unkovn etiology and in those positive.for hepatitis C virus RNA. J of Hepatology
1999;30:205-212.
8. Matsumoto A, Yeo AET, Shih JWK, et al. Transfusion-associated TT virus infection and its relationship to
liver disease. Hepatology 1999;30: 283-288.
9. Okomato H, Akahane Y, Ukita M, et al. Fecal excretion of a non-enveloped DNA virus (TTV) associated with posttransfusion non-A-G hepatitis. J of Med Virol
1998;56: 128-139.
10. Ukita M, Okamoto H, Kato N, et al. Excretion in to bile of a novel unenveloped DNA virus (TTV virus) associated with acute and chronic non-A-G hepatitis. J
of Infect Dis 1999;179: 1245-1248.
11. Dumman H, Meurr S, Meyer Z, Biichenfelde KH, Kohler H. Hepattis B vaccination and interleukin 2 receptor expression in chronic renal failure. Kidney Int
1990;38: 1165-69.
12. Özener Ç, Fak AS, Avşar E, ve ark. The effect of alpha interferon therapy and short interval intradermal administration ofn response to hepatitis B vaccine in haemodialysis patients.Nephrol Dial Transplant
1999;14: 1339-40.
13. Barril G, Lopez-Alcorocho JM, Bajo A et al. Prevalence of TT virus in serum and peripheral mononuclear cells
from a CAPD population. Perit Dial Int 2000;20: 65-69.
14. Ikeychi T, Okuda K, Yokosuka O et al: Superinfection of TT virus and hepattis C virus among chronic haemodialysis patients. J Gastroenterol Hepatol 1999;14:796-800.
15. Forns X, Hegerich P, Darnell A, et al. High prevalence of TT virus (TTV) infection in patients on maintanence haemodialysis: Frequent mixt infections with different genotypes and lack of evidence of associated liver
disease. J Med Virol 1999;59: 313-317.
16. Yuki N, Kato NM, Masuzawa M et al: Clinical implications of coinfection with a novel DNA virus (TTV) in hepattis C virus carriers on maintanence
hemodialysis. J Med Virol 1999:59; 431-436.

Thank you for copying data from http://www.arastirmax.com